In Brief: Cygnus
This article was originally published in The Tan Sheet
Cygnus: Nicotrol sales rise to $5.6 mil. in the second quarter, the firm notes. The sales figure includes U.S. and European product sales and royalties from McNeil Consumer Products, which licenses the smoking cessation transdermal patch. Cygnus increased shipments of Nicotrol in the quarter in anticipation of FDA's July 3 approval of the Rx-to-OTC switch ("The Tan Sheet" July 8, p. 1)...
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC